{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:25:11Z","timestamp":1777580711444,"version":"3.51.4"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Lupin Limited"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.ejphar.2018.03.034","type":"journal-article","created":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T21:14:43Z","timestamp":1521753283000},"page":"31-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Bilateral quinolinic acid-induced lipid peroxidation, decreased striatal monoamine levels and neurobehavioral deficits are ameliorated by GIP receptor agonist D-Ala 2 GIP in rat model of Huntington's disease"],"prefix":"10.1016","volume":"828","author":[{"given":"Mahip K.","family":"Verma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajan","family":"Goel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishnadas","family":"Nandakumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumar V.S.","family":"Nemmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2018.03.034_bib1","series-title":"Huntington's Disease","author":"Bates","year":"2002"},{"key":"10.1016\/j.ejphar.2018.03.034_bib2","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1523\/JNEUROSCI.11-06-01649.1991","article-title":"Chronic quinolinic acid lesions in rats closely resemble Huntington's disease","volume":"11","author":"Beal","year":"1991","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2018.03.034_bib3","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/321168a0","article-title":"Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid","volume":"321","author":"Beal","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2018.03.034_bib4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.parkreldis.2011.05.012","article-title":"Serotonin and dopamine striatal innervation in Parkinson's disease and Huntington's chorea","volume":"17","author":"Bedard","year":"2011","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.ejphar.2018.03.034_bib5","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1038\/sj.bjp.0702940","article-title":"Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl","volume":"128","author":"Behan","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.03.034_bib6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0940-2993(11)80189-2","article-title":"Quinolinic acid: effects on brain catecholamine and c-AMP content during L-dopa and reserpine administration","volume":"44","author":"Beskid","year":"1992","journal-title":"Exp. Toxicol. Pathol."},{"key":"10.1016\/j.ejphar.2018.03.034_bib7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0006-8993(86)90362-8","article-title":"Short- and long-term consequences of intracranial injections of the excitotoxin, quinolinic acid, as evidenced by GFA immunohistochemistry of astrocytes","volume":"371","author":"Bjorklund","year":"1986","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2018.03.034_bib8","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1742-4658.2009.07487.x","article-title":"Neuroprotective effects of naturally occurring polyphenols on quinolinic acid-induced excitotoxicity in human neurons","volume":"277","author":"Braidy","year":"2010","journal-title":"FEBS J."},{"key":"10.1016\/j.ejphar.2018.03.034_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40265-016-0670-4","article-title":"Current pharmacological approaches to reduce chorea in Huntington's disease","volume":"77","author":"Coppen","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2018.03.034_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fnsys.2011.00031","article-title":"Noradrenaline and Parkinson's disease","volume":"5","author":"Delaville","year":"2011","journal-title":"Front. Syst. Neurosci."},{"key":"10.1016\/j.ejphar.2018.03.034_bib11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00702-009-0364-0","article-title":"Oxidative stress and plasma aminopeptidase activity in Huntington's disease","volume":"117","author":"Duran","year":"2010","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.ejphar.2018.03.034_bib12","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1152\/jn.00866.2010","article-title":"Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis","volume":"105","author":"Faivre","year":"2011","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.ejphar.2018.03.034_bib13","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ejphar.2011.11.007","article-title":"Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice","volume":"674","author":"Faivre","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.03.034_bib14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3233\/JAD-121888","article-title":"D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse model","volume":"35","author":"Faivre","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ejphar.2018.03.034_bib15","series-title":"Huntington's Disease: A Disorder of Families","author":"Folstein","year":"1989"},{"key":"10.1016\/j.ejphar.2018.03.034_bib16","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pharep.2016.11.008","article-title":"Sertraline and venlafaxine improves motor performance and neurobehavioral deficit in quinolinic acid induced Huntington's like symptoms in rats: possible neurotransmitters modulation","volume":"69","author":"Gill","year":"2017","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejphar.2018.03.034_bib17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3233\/JHD-120023","article-title":"Cognitive dysfunction in Huntington's disease: humans, mouse models and molecular mechanisms","volume":"1","author":"Giralt","year":"2012","journal-title":"J. Huntingt. Dis."},{"key":"10.1016\/j.ejphar.2018.03.034_bib18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.neuron.2005.03.025","article-title":"Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice","volume":"46","author":"Gu","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.ejphar.2018.03.034_bib19","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/BF00310376","article-title":"Cortical and striatal neurone number in Huntington's disease","volume":"88","author":"Heinsen","year":"1994","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejphar.2018.03.034_bib20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0022-510X(94)90343-3","article-title":"Muscle tone in Huntington's disease","volume":"121","author":"Homberg","year":"1994","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ejphar.2018.03.034_bib21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0306-4522(85)90095-8","article-title":"Neural grafting in a rat model of Huntington's disease: progressive neurochemical changes after neostriatal ibotenate lesions and striatal tissue grafting","volume":"16","author":"Isacson","year":"1985","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2018.03.034_bib22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12640-015-9535-y","article-title":"Protective effect of spermidine against excitotoxic neuronal death induced by quinolinic acid in rats: possible neurotransmitters and neuroinflammatory mechanism","volume":"28","author":"Jamwal","year":"2015","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.ejphar.2018.03.034_bib23","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.lfs.2011.02.020","article-title":"Suppressing inflammatory cascade by cyclooxygenase inhibitors attenuates quinolinic acid induced Huntington's disease-like alterations in rats","volume":"88","author":"Kalonia","year":"2011","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2018.03.034_bib24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.pbb.2010.04.018","article-title":"Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: possible role of peroxisome proliferator activated receptor-Upsilon (PPARUpsilon) in Huntington's disease","volume":"96","author":"Kalonia","year":"2010","journal-title":"Pharmacol. Biochem Behav."},{"key":"10.1016\/j.ejphar.2018.03.034_bib25","first-page":"880","article-title":"Neuroprotective effect of MK-801 against intra-striatal quinolinic acid induced behavioral, oxidative stress and cellular alterations in rats","volume":"47","author":"Kalonia","year":"2009","journal-title":"Indian J. Exp. Biol."},{"key":"10.1016\/j.ejphar.2018.03.034_bib26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0196-9781(94)90016-7","article-title":"Gastric inhibitory polypeptide (GIP) binding sites in rat brain","volume":"15","author":"Kaplan","year":"1994","journal-title":"Peptides"},{"key":"10.1016\/j.ejphar.2018.03.034_bib27","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1007\/s00415-007-0611-y","article-title":"Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects: a cross-sectional study","volume":"254","author":"Klepac","year":"2007","journal-title":"J. Neurol."},{"key":"10.1016\/j.ejphar.2018.03.034_bib28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejphar.2013.10.057","article-title":"Minocycline modulates neuroprotective effect of hesperidin against quinolinic acid induced Huntington's disease like symptoms in rats: behavioral, biochemical, cellular and histological evidences","volume":"720","author":"Kumar","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.03.034_bib29","doi-asserted-by":"crossref","first-page":"11783","DOI":"10.3390\/ijms130911783","article-title":"Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters","volume":"13","author":"Lee","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2018.03.034_bib30","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ijdevneu.2005.08.004","article-title":"Quinolinic acid reduces the antioxidant defenses in cerebral cortex of young rats","volume":"23","author":"Leipnitz","year":"2005","journal-title":"Int J. Dev. Neurosci."},{"key":"10.1016\/j.ejphar.2018.03.034_bib31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fnsys.2014.00016","article-title":"Cognitive-motor interactions of the basal ganglia in development","volume":"8","author":"Leisman","year":"2014","journal-title":"Front. Syst. Neurosci."},{"key":"10.1016\/j.ejphar.2018.03.034_bib32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neuropharm.2015.10.002","article-title":"Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model","volume":"101","author":"Li","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2018.03.034_bib33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejphar.2016.11.050","article-title":"D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation","volume":"797","author":"Li","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.03.034_bib34","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1038\/sj.npp.1300777","article-title":"The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat","volume":"30","author":"Lieben","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2018.03.034_bib35","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s12640-014-9469-9","article-title":"Improvement of mitochondrial function by paliperidone attenuates quinolinic acid-induced behavioural and neurochemical alterations in rats: implications in Huntington's disease","volume":"26","author":"Mishra","year":"2014","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.ejphar.2018.03.034_bib36","doi-asserted-by":"crossref","first-page":"e18336","DOI":"10.1371\/journal.pone.0018336","article-title":"Altered dopamine and serotonin metabolism in motorically asymptomatic R6\/2 mice","volume":"6","author":"Mochel","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2018.03.034_bib37","first-page":"21","article-title":"Brain imaging and cognitive dysfunctions in Huntington's disease","volume":"31","author":"Montoya","year":"2006","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.ejphar.2018.03.034_bib38","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1523\/JNEUROSCI.4920-04.2005","article-title":"Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation","volume":"25","author":"Nyberg","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2018.03.034_bib39","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/jnr.21349","article-title":"Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain","volume":"85","author":"Nyberg","year":"2007","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.ejphar.2018.03.034_bib40","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.neuint.2010.03.008","article-title":"Time-course correlation of early toxic events in three models of striatal damage: modulation by proteases inhibition","volume":"56","author":"Perez-De La Cruz","year":"2010","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejphar.2018.03.034_bib41","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1111\/febs.12762","article-title":"Biochemical, histopathological and behavioral alterations caused by intrastriatal administration of quinolic acid to young rats","volume":"281","author":"Pierozan","year":"2014","journal-title":"FEBS J."},{"key":"10.1016\/j.ejphar.2018.03.034_bib42","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0361-9230(94)90109-0","article-title":"Behavioral and electrophysiological correlates of the quinolinic acid rat model of Huntington's disease in rats","volume":"35","author":"Popoli","year":"1994","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ejphar.2018.03.034_bib43","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1046\/j.1471-4159.1999.721773.x","article-title":"Brain neurotransmitter deficits in mice transgenic for the Huntington's disease mutation","volume":"72","author":"Reynolds","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2018.03.034_bib44","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/BF00966592","article-title":"Quinolinic acid is a potent lipid peroxidant in rat brain homogenates","volume":"16","author":"Rios","year":"1991","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ejphar.2018.03.034_bib45","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0006-8993(99)02474-9","article-title":"Effect of quinolinic acid on endogenous antioxidants in rat corpus striatum","volume":"858","author":"Rodriguez-Martinez","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2018.03.034_bib46","first-page":"137","article-title":"Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease","volume":"50","author":"Roitberg","year":"2002","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ejphar.2018.03.034_bib47","doi-asserted-by":"crossref","first-page":"13804","DOI":"10.1073\/pnas.0702753104","article-title":"Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice","volume":"104","author":"Rommelfanger","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejphar.2018.03.034_bib48","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1750-1172-5-40","article-title":"Huntington's disease: a clinical review","volume":"5","author":"Roos","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ejphar.2018.03.034_bib49","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington's disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2018.03.034_bib50","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1073\/pnas.1314421111","article-title":"HACE1 reduces oxidative stress and mutant Huntingtin toxicity by promoting the NRF2 response","volume":"111","author":"Rotblat","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejphar.2018.03.034_bib51","doi-asserted-by":"crossref","first-page":"13915","DOI":"10.1073\/pnas.0502878102","article-title":"Antioxidants modulate mitochondrial PKA and increase CREB binding to D-loop DNA of the mitochondrial genome in neurons","volume":"102","author":"Ryu","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejphar.2018.03.034_bib52","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.expneurol.2004.01.006","article-title":"Blockade of quinolinic acid-induced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington's disease","volume":"187","author":"Ryu","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2018.03.034_bib53","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0014-4886(89)90170-2","article-title":"The quinolinic acid model of Huntington's disease: locomotor abnormalities","volume":"105","author":"Sanberg","year":"1989","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2018.03.034_bib54","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bbr.2003.10.021","article-title":"Progressive behavioural changes in the spatial open-field in the quinolinic acid rat model of Huntington's disease","volume":"152","author":"Scattoni","year":"2004","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejphar.2018.03.034_bib55","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/ana.410020407","article-title":"Inhibitors of GABA metabolism: implications for Huntington's disease","volume":"2","author":"Schwarcz","year":"1977","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2018.03.034_bib56","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.pneurobio.2009.04.005","article-title":"Of mice, rats and men: revisiting the quinolinic acid hypothesis of Huntington's disease","volume":"90","author":"Schwarcz","year":"2010","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejphar.2018.03.034_bib57","doi-asserted-by":"crossref","first-page":"34880","DOI":"10.1074\/jbc.M804183200","article-title":"Huntingtin regulates RE1-silencing transcription factor\/neuron-restrictive silencer factor (REST\/NRSF) nuclear trafficking indirectly through a complex with REST\/NRSF-interacting LIM domain protein (RILP) and dynactin p150 Glued","volume":"283","author":"Shimojo","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2018.03.034_bib58","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000443896","article-title":"Neuroprotective activity of curcumin in combination with piperine against quinolinic acid induced neurodegeneration in rats","volume":"97","author":"Singh","year":"2016","journal-title":"Pharmacology"},{"key":"10.1016\/j.ejphar.2018.03.034_bib59","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ejcb.2017.03.004","article-title":"Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factors","volume":"96","author":"Spielman","year":"2017","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.ejphar.2018.03.034_bib60","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0197-0186(97)90002-4","article-title":"The effect of quinolinate on rat brain lipid peroxidation is dependent on iron","volume":"30","author":"Stipek","year":"1997","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejphar.2018.03.034_bib61","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1210\/endo.133.6.8243312","article-title":"Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain","volume":"133","author":"Usdin","year":"1993","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2018.03.034_bib62","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejphar.2017.03.059","article-title":"Effect of D-Ala2GIP, a stable GIP receptor agonist on MPTP-induced neuronal impairments in mice","volume":"804","author":"Verma","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.03.034_bib63","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pharep.2013.10.002","article-title":"An anti-immobility effect of spermine in the forced swim test in mice","volume":"66","author":"Wosko","year":"2014","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejphar.2018.03.034_bib64","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fnagi.2017.00193","article-title":"Microglial activation in the pathogenesis of Huntington's disease","volume":"9","author":"Yang","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejphar.2018.03.034_bib65","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1046\/j.1471-4159.2002.01084.x","article-title":"Inhibition of tryptophan hydroxylase activity and decreased 5-HT1A receptor binding in a mouse model of Huntington's disease","volume":"82","author":"Yohrling","year":"2002","journal-title":"J. Neurochem."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918301948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918301948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:18:55Z","timestamp":1604017135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299918301948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":65,"alternative-id":["S0014299918301948"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.03.034","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bilateral quinolinic acid-induced lipid peroxidation, decreased striatal monoamine levels and neurobehavioral deficits are ameliorated by GIP receptor agonist D-Ala2GIP in rat model of Huntington's disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.03.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}